Savara is a pre-revenue biotechnology company in a golden cross breakout with 78% analyst price target upside, but quality scores only 1.6 out of 10 with fully negative free cash flow and a put/call ratio of 28.33 — the highest in this group — signaling extreme options market bearishness despite the bullish technical setup.
Thesis pillars
- Extreme Put Call Bearish Signal↑Improving
- Bullish Breakout Technical Setup↓Deteriorating
- Quality Below Floor Cash Burn→Stable
- +1 more pillar — see the Why tab for full reasoning
Savara, Inc. (SVRA) Stock Analysis
Inst Constrain edge
Healthcare · Biotechnology
Sell if holding. Engine safety override at $5.51: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.7/10 and A.R:R 7.4:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 18%; Below-average business quality; Negative price momentum.
Savara is a clinical-stage biopharmaceutical company developing MOLBREEVI, an inhaled GM-CSF biologic and its sole product candidate, for autoimmune pulmonary alveolar proteinosis, a rare lung disease with no FDA-approved treatments. The company has no approved products or... Read more
Sell if holding. Engine safety override at $5.51: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.7/10 and A.R:R 7.4:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 18%; Below-average business quality; Negative price momentum. Chart setup: No clear chart pattern; technical signals are mixed. Score 4.7/10, moderate confidence.
Passes 6/8 gates (favorable risk/reward ratio, no SEC red flags, news events none recent, earnings proximity 25d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: speculative.
Recent developments
updated 2026-07-20Recent Developments — Savara, Inc.
Latest news
- NEWS Savara Chief Financial And Administrative Officer Dave Lowrance Stepping Down, Effective July 15; COO Robert Lutz To Ass — benzinga Jun 8, 2026 negative
- NEWS Savara Presents New Biomarker Data From Double-Blind Period Of IMPALA-2 Phase 3 Clinical Trial Evaluating Molgramostim F — benzinga May 20, 2026 positive
- NEWS Savara Presents New Exercise Capacity Data From Double-Blind Period Of IMPALA-2 Phase 3 Clinical Trial Evaluating Molgra — benzinga May 18, 2026 positive
- NEWS Savara Q1 EPS $(0.15) Misses $(0.14) Estimate — benzinga May 12, 2026 negative
- NEWS Savara Announces FDA Extends Review Period For Molgramostim Inhalation Solution Biologics License Application In Autoimm — benzinga Apr 15, 2026 negative
Generated 2026-07-20T05:32:11Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
4 floor-breakers·1 ceiling hit
Quality below the gate floor. Component breakdown shows what dragged the score down.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $5.51: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.7/10 and A.R:R 7.4:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 18%; Below-average business quality; Negative price momentum. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $5.21. Score 4.7/10, moderate confidence.
Take-profit target: $9.52 (+72.4% upside). Prior stop was $5.21. Stop-loss: $5.21.
Quality below floor (1.6 < 4.0); Value-trap signals (3/5): Margin compression (op margin -3.8%), Material insider selling (5 sells, 0.09% of cap), Negative free cash flow.
Savara, Inc. trades at a P/E of N/A (forward -18.8). TrendMatrix value score: 9.0/10. Verdict: Sell.
14 analysts cover SVRA with a consensus score of 4.3/5. Average price target: $11.
What does Savara, Inc. do?Savara is a clinical-stage biopharmaceutical company developing MOLBREEVI, an inhaled GM-CSF biologic and its sole...
Savara is a clinical-stage biopharmaceutical company developing MOLBREEVI, an inhaled GM-CSF biologic and its sole product candidate, for autoimmune pulmonary alveolar proteinosis, a rare lung disease with no FDA-approved treatments. The company has no approved products or commercial revenue; the FDA formally filed Savara's resubmitted Biologics License Application for MOLBREEVI in February 2026 and granted Priority Review. Savara outsources manufacturing to third-party partners including Fujifilm for drug substance and PARI for its proprietary nebulizer delivery device.